Eligibility Criteria:
Selection criteria :
Criteria related to the population:
* Woman aged between 18 and 50 years old included
* Phototype I to IV included, according to Fitzpatrick classification
* Subject having signed written informed consent for the participation in the study
* Subject affiliated to a social security system or health insurance, or is a beneficiary of either (if required by national regulation)
* Subject whose last shampoo has been done at least 2 days before the selection visit
* Use of a contraceptive method assessed as efficient by an investigator (including tubal ligation), started since at least 3 months before the selection visit, continued during the study and until after 1 month after the study end
* Subject having hair length of at least 5 cm
Criteria related to diseases and hair loss disorder:
\- Subject having effluvium telogen
Non selection criteria :
Criteria related to the population:
* Pregnant or breastfeeding women or planning to being pregnant during the study
* Perimenopausal symptoms (irregular menstruations, premenstrual syndrome …) or menopausal symptoms (climacteric troubles: hot flush, headaches, tiredness, insomnia, irritability …)
* Menopause (absence of menstruations since at least 1 year) or a bilateral ovariectomy
* Subject having frizzy hair
* Subject who has forfeited her freedom by administrative or legal award or is under guardianship
* Subject who, according to the judgement of the investigator, is unlikely to be compliant during the study
* Subject unable to understand the information given (for linguistic or psychiatric reasons) and to give her consent in writing to participate
* Subject who is currently participating in any another clinical trial
* Subject who has participated in another clinical trial with hair product or treatment (local on the scalp and/or systemic) within the last 12 weeks before the selection visit
Criteria related to diseases and hair loss disorders:
\- Subject who has any other hair disorder or hair disease (Ludwig II, III, AA, scarring alopecia …)
Criteria related to the population:
* Pregnant or breastfeeding women or planning to being pregnant during the study
* Perimenopausal symptoms (irregular menstruations, premenstrual syndrome …) or menopausal symptoms (climacteric troubles: hot flush, headaches, tiredness, insomnia, irritability …)
* Menopause (absence of menstruations since at least 1 year) or a bilateral ovariectomy
* Subject having frizzy hair
* Subject who has forfeited her freedom by administrative or legal award or is under guardianship
* Subject who, according to the judgement of the investigator, is unlikely to be compliant during the study
* Subject unable to understand the information given (for linguistic or psychiatric reasons) and to give her consent in writing to participate
* Subject who is currently participating in any another clinical trial
* Subject who has participated in another clinical trial with hair product or treatment (local on the scalp and/or systemic) within the last 12 weeks before the selection visit
Criteria related to diseases and hair loss disorders:
* Subject who has any other hair disorder or hair disease (Ludwig II, III, AA, scarring alopecia …)
* History or clinical signs of hyperandrogenemia (menstrual cycle \>35 days and hirsutism and signs of acne)
* Inflammatory skin disease or progressive skin lesion on the scalp (psoriasis, seborrheic dermatitis, severe erythema, severe excoriation, severe sunburn, etc.).
* Neoplastic disease at any time
* History of hypersensitivity or intolerance to any of the following components applied by topical route: ethyl alcohol, components of the used hair dye, components of the RV3466F lotion
* Thyroid disorders stabilised for less than 3 months
Criteria related to treatments and products:
* Systemic treatment affecting the hair growth taken for more than 4 weeks during the last 12 weeks before the selection visit:
* Finasteride
* Dutasteride
* Retinoids
* Anti-mitotic, cytotoxic drugs other than antineoplastic
* Spironolactone, flutamide, and all androgens
* Anti-epileptic agents, interferon alpha
* Minoxidil, Aminexil applied on the scalp within the last 24 weeks before the selection visit
* Systemic or local anti hair loss treatment or product, taken or applied (cosmetic solution or capsules with vitamin B, zinc, caffeine…) within the last 4 weeks before the selection visit.
* Drugs for thyroid disorders, if non stabilized for at least 3 months,
* Iron supplement if not started for at least 3 months
* Any hair care or styling method within the last week before the selection visit (e.g. dyeing, bleaching, perm, straightening, …)
* Any hair care product applied on the scalp between the last shampoo and the selection visit (e.g. gel, hairspray, wax, foam, …) or water or brushing.
* Any food supplements for hair growth taken for more than 4 weeks during the 12 weeks before the selection visit
* Radiotherapy, chemotherapy at any time
* Scalp surgery (hair transplants, laser) within the 12 months before the selection visit
Inclusion criteria :
* Criteria related to hair loss disorder:
* Subject having a proportion of hair in telogen phase superior to 15% (determined by phototrichogram at inclusion) on the centroparietal area of the scalp
* Subject having a total hair density superior or equal to ≥ 220 hairs/ cm2 (determined by phototrichogram at inclusion) on the centroparietal area of the scalp
Non inclusion criteria :
* Criteria related to treatments and products:
* Any hair care product applied on the scalp between the selection visit and the inclusion visit (e.g. gel, hairspray, wax, foam, …) or water or brushing.
* Reaction to the used hair dye during the inclusion visit